KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Assets Average (2016 - 2025)

Historic Assets Average for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $100.5 million.

  • Arbutus Biopharma's Assets Average fell 3311.56% to $100.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.5 million, marking a year-over-year decrease of 3311.56%. This contributed to the annual value of $138.1 million for FY2024, which is 1874.87% down from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Assets Average is $100.5 million, which was down 3311.56% from $110.1 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Assets Average ranged from a high of $226.4 million in Q2 2022 and a low of $100.5 million during Q3 2025
  • Over the past 5 years, Arbutus Biopharma's median Assets Average value was $151.5 million (recorded in 2023), while the average stood at $162.9 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Assets Average surged by 6075.54% in 2022, and later plummeted by 3311.56% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Assets Average stood at $185.0 million in 2021, then increased by 7.87% to $199.6 million in 2022, then fell by 24.09% to $151.5 million in 2023, then decreased by 10.19% to $136.1 million in 2024, then fell by 26.15% to $100.5 million in 2025.
  • Its Assets Average stands at $100.5 million for Q3 2025, versus $110.1 million for Q2 2025 and $124.4 million for Q1 2025.